Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

9.135 -0.065 (-0.71%)
Streaming Delayed Price Updated: 3:52 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms
Analysts have also noted that the relatively low breakup fee may leave room for a competing offer, possibly from Biogen. 
Via Stocktwits
Deep Dive Into Sage Therapeutics Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News
Via Benzinga
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
Via Benzinga
US Stock Futures Tumble After Trump Threatens 'Real End' To Iran's Nuclear Problem: '...Avoid Getting Whipsawed By Noise,' Says Expert
U.S. stock futures were trading lower on Tuesday following Monday's advanced. Futures of major benchmark indices were lower in premarket. 
Via Benzinga
Topics Government
Earnings Scheduled For April 29, 2025
Via Benzinga
What to Expect from Sage Therapeutics's Earnings
Via Benzinga
A Glimpse Into The Expert Outlook On Sage Therapeutics Through 7 Analysts
Via Benzinga
Dow Surges Over 300 Points As Iran Signals De-Escalation: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone
Via Benzinga
Topics Stocks
Monday's session: top gainers and losers
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
S&P 500 Surges 1%; New York Manufacturing Activity Tumbles In June
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Top movers in Monday's session
Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics
Under the terms of the deal, Supernus is looking to acquire Sage for a total consideration of $12 per share in cash. 
Via Stocktwits
Topics Government
Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday
Via Benzinga
These stocks are gapping in today's session
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal
Supernus to acquire Sage Therapeutics for $795 million, gaining Zurzuvae and aiming for $200 million in annual cost synergies by expanding its CNS portfolio. 
Via Benzinga
Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million
The deal expands Supernus Pharmaceuticals' presence in the nonpsychiatric space. 
Via Investor's Business Daily
Topics ETFs
Monday's pre-market session: top gainers and losers
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Expert Outlook: Sage Therapeutics Through The Eyes Of 4 Analysts
Via Benzinga
US Stocks Likely To Open Mixed: 'Expect Volatility. Buckle Up,' Says Expert
U.S. stock futures were swinging between gains and losses on Thursday after snapping a three-day winning streak on Wednesday. Futures of major benchmark indices were mixed in premarket trading. Aiming... 
Via Benzinga
Topics Supply Chain World Trade
KB Home Posts Downbeat Results, Joins UniFirst, Oklo And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Why Power Solutions International Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
What To Expect From Alzheimer's Drugmaker Biogen's Q4 Earnings On Wednesday?
Biogen faces revenue challenges as Leqembi sales lag projections. Investors watch its pipeline expansion and strategic moves amid upcoming Q4 earnings. 
Via Benzinga
Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok
Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on TikTok. 
Via Benzinga
Earnings Scheduled For February 11, 2025
Via Benzinga
Biogen Rises On FDA Nod for Alzheimer's Drug Dosing Regimen, But Sage Deal Fallout Irks Retail
The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders. 
Via Stocktwits
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company. 
Via Benzinga
Topics Government
Sage Therapeutics Stock Eyes Best Day In 5 Years On Biogen’s Unsolicited Bid: Retail Piles In
The two companies have collaborated since 2020 on the depression drug Zurzuvae, approved in 2023 by the FDA for treating postpartum depression. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.